Antiretroviral therapy in children

Southern African Journal of HIV Medicine

Volumn , Issue 9, 2002, Pages 23-33

  Levin, Leon ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; AZITHROMYCIN; CISAPRIDE; CLARITHROMYCIN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MIDAZOLAM; NELFINAVIR; NEVIRAPINE; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRA CEPT; VIRUS RNA; ZIDOVUDINE;

ARTICLE; BLOOD TOXICITY; CHILD; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG METABOLISM; DRUG RESPONSE; EUROPE; EXPERIENCE; GASTROINTESTINAL TOXICITY; HELPER CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; INFANT; LONG TERM CARE; LYMPHOCYTE COUNT; MEDICAL DECISION MAKING; MEDICAL EDUCATION; MEDICAL SOCIETY; NEUROTOXICITY; PATIENT COMPLIANCE; PATIENT MONITORING; PRACTICE GUIDELINE; SOUTH AFRICA; TUBERCULOSIS; VIRUS LOAD; WORKSHOP; WORLD HEALTH ORGANIZATION;

EID: 0036813898     PISSN: 16089693     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Centres for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in paediatrics practice. MMWR 1998; 47: 1-43. Published and updated regularly on the web www.hivatis.org
2. Scaling up Antiretroviral Therapy in Resource-limited settings. Guidelines for a public Health Approach. Executive summary April 2002. www.who.int
3. Sharland M, Castelli G, Ramos JT, Blanche S, Gibb DM. On behalf of the PENTA Steering Committee Penta Guidelines for the use of Antiretroviral Therapy in Paediatric HIV Infection, www.ctu.mrc.ac.uk/PENTA/
4. Shearer WT, Quinn TC, LaRussa P, et al. Viral load and disease progression in infants with human immunodeficiency virus type 1. N Engl J Med 1997; 336: 1337-1342.
5. Mofenson LM, Korelitz J, Meyer WA, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1 infected children. J Infect Dis 1997; 175: 1029-1038.
6. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in paediatric HIV infection. MMWR 1998; 47: 1-39.
7. Centers for Disease Control. 1994 Revised classification system for human immunodeficiency virus infection in children less than 13 years od age. MMWR 1994; 43: 1-12.
8. Nachman S, Stanley K, Yogev R, et al. Nucleoside analogues plus ritonavir in stable antiretroviral therapy-experienced HIV-experienced children - a randomized controlled trial. JAMA 2000; 283: 492-498.
9. Krogstad P, Wiznia A., Luzuriaga K, et al. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis 1999; 28: 1109-1118.
10. Van Rossum AMC, Niesters HGM, Geelen SPM, et al. Clinical and viologic response to combination treatment with indinavir, zidovudine and lamivudine in children with human immunodeficiency virus type-1 infection: a multicenter study in the Netherlands. J Pediatr 2000; 136: 780-788.
11. Starr SE, Fletcher CV, Spector SA, et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transciptase inhibitors in children infected with human immunodeficiency virus type 1. N Engl J Med 1999; 341: 1874-1881.
12. Luzuriage K, Mcmanus K, Catalina M, et al. Early therapy of vertical human immunodeficiency virus type 1 (HIV) infection: control of viral replication and absence of persistent HIV-1 specific immune response. J Virol 2000; 74: 6987-6991.
13. Tudor-Williams G, Head S, Weigel R, Valerius NH, Riddell A, Lyall EGH. Baby Cocktaill A protease-sparing 4 drug combination for symptomatic infants. 14th International AIDS Conference, Barcelona, 7-12 July 2002 (Abstract MoOrB1129).
14. Gibb DM. on behalf of the Paediatric European Network for Treatment of AIDS (PENTA) Writing Committee. Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet 2002; 359: 733-740.
15. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15: 1951-1957.
16. Eastman PS, Shapiro DE, Coombs RW, et al. Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998; 177: 557-564.
17. McSherry GD, Shapiro DE, Coombs RW, et al. The effects of zidovudine in the subset of infants infected with human immunodeficiency virus type 1 (Pediatric AIDS Clinical Trials Group Protocol 076). J Pediatr 1999; 134: 717-724.
18. Stiehman ER, Lambert J, Mofenson LM, et al, Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobin for reducing perinatal HIV transmission for HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group Protocol 185. J Infect Dis 1999; 179: 567-575.
19. Mandelbrot L, Landreau-Mascaro A, Rekacewicz A, et al. Lamiduvine-zidovudine for prevention of maternal-infant transmission of HIV-1. JAMA 2001; 285: 2083-2093.
20. Burman WJ, Jones BE. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med 2001; 164: 7-12.
21. Centers for Disease Control. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR 2000; 49: 185-189.